Infusion of CD19 CAR-T cells from HLA-mismatched donors improved skin sclerosis and lung function in refractory SSc patientsPhase I multicenter trials showed significant reduction in disease activity scores after a single infusion of CD19 CAR-T cells in SSc patientsGenetically edited allogeneic CD19 CAR-T therapy improved organ function in refractory necrotizing myopathy and diffuse SSc patients. This evidence concerns the gene CD19 and systemic sclerosis.